Eli Lilly’s recently-announced alternative to Humalog, an insulin drug, is set to carry half the list price at about $137.35 per vial and $265.20 for five pens, according to a FiercePharma report.
Vamil Divan, Credit Suisse analyst, says the decision could be beneficial to easing two key pressure points.
“Given the controversy around insulin pricing with high list prices but also large discounts, we think this makes sense to lower out of pocket costs and also ease public pressure on manufacturers,” Divan reportedly wrote in a memo on Monday.
The drugmaker said offering the new drug, called Lispro, was faster than dropping Humalog’s price to lower out-of-pocket costs for patients, and that the decision also gives “payers time to renegotiate downstream contracts and adjust to new system economics.”
To read the full report on FiercePharma, click here.